DaVita Inc. (DVA) EV/FCF Ratio: 18.01x
Is DaVita Inc.’s EV/FCF ratio high or low?
DaVita Inc.'s EV/FCF ratio of 18.01x is in line with its 5-year average of 18.17x, around the middle of its 5-year range (12.96x–26.92x).
As of Wednesday, June 17, 2026. 2.97% above its 12-month average of 17.49x.
DVA EV/FCF Ratio Chart
DVA Average EV/FCF Ratio Chart
DVA Current vs Average EV/FCF Ratio Chart
DVA EV/FCF Ratio Metrics
EV/FCF RATIO
18.01x
EV/FCF RATIO AVG TTM
17.49x
EV/FCF RATIO AVG 3Y
16.95x
EV/FCF RATIO AVG 5Y
18.11x
EV/FCF RATIO AVG 10Y
18.85x
EV/FCF RATIO AVG 15Y
20.67x
EV/FCF RATIO AVG 20Y
23.33x
CURRENT VS TTM AVG
+2.97%
CURRENT VS 3Y AVG
+6.23%
CURRENT VS 5Y AVG
-0.55%
CURRENT VS 10Y AVG
-4.44%
CURRENT VS 15Y AVG
-12.87%
CURRENT VS 20Y AVG
-22.82%
DVA Competitors' EV/FCF Ratio
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DaVita Inc. (DVA) | $13.46B | 18.01x | 17.49x | 16.95x | 18.11x |
| The Cooper Companies, Inc. (COO)vs › | $13.14B | 27.14x | 39.65x | 81.72x | 66.10x |
| Medpace Holdings, Inc. (MEDP)vs › | $13.05B | 17.22x | 21.70x | 22.24x | 22.58x |
| Solventum Corporation (SOLV)vs › | $12.91B | N/A | 157.09x | 88.54x | 88.54x |
| Align Technology, Inc. (ALGN)vs › | $12.86B | 17.36x | 17.68x | 29.40x | 38.81x |
| Revvity, Inc. (RVTY)vs › | $10.91B | 27.20x | 26.78x | 265.85x | 164.10x |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 66.60x | 67.40x | 78.57x | 42.55x |
| Baxter International Inc. (BAX)vs › | $10.19B | 25.50x | 66.70x | 51.59x | 47.30x |
| Hologic, Inc. (HOLX)vs › | $16.97B | 17.53x | 16.94x | 18.67x | 15.16x |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.90B | 30.44x | 21.43x | 28.98x | 35.20x |
Cash Flow Valuation Comparison
EV/FCF
18.0x
P/FCF
9.6x
FCF Yield
10.37%
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
- EV/FCF accounts for debt and cash through enterprise value
- P/FCF only considers equity value
- EV/FCF can be compared across companies with different debt levels
- Both measure how the market values cash generation
DaVita Inc. EV/FCF Ratio Formula & Definition
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DaVita Inc. EV/FCF Ratio FAQ
- What is the EV/FCF ratio for DaVita Inc. (DVA)?
- The EV/FCF ratio for DVA stock is 18.01x.
- Is DaVita Inc.'s EV/FCF ratio high or low?
- DaVita Inc.'s EV/FCF ratio of 18.01x is in line with its 5-year average of 18.17x, around the middle of its 5-year range (12.96x–26.92x).
- What is the TTM average EV/FCF ratio for DaVita Inc. (DVA)?
- The TTM average EV/FCF ratio for DVA stock is 17.49x.
- What is the 3Y average EV/FCF ratio for DaVita Inc. (DVA)?
- The 3Y average EV/FCF ratio for DVA stock is 16.95x.
- What is the 5Y average EV/FCF ratio for DaVita Inc. (DVA)?
- The 5Y average EV/FCF ratio for DVA stock is 18.11x.
- What is the 10Y average EV/FCF ratio for DaVita Inc. (DVA)?
- The 10Y average EV/FCF ratio for DVA stock is 18.85x.
- What is the 15Y average EV/FCF ratio for DaVita Inc. (DVA)?
- The 15Y average EV/FCF ratio for DVA stock is 20.67x.
- What is the 20Y average EV/FCF ratio for DaVita Inc. (DVA)?
- The 20Y average EV/FCF ratio for DVA stock is 23.33x.
DaVita Inc. EV/FCF Ratio History
| DATE | EV/FCF RATIO |
|---|---|
| 2026-06-15 | 18.05x |
| 2026-06-12 | 18.00x |
| 2026-06-11 | 17.78x |
| 2026-06-10 | 17.53x |
| 2026-06-09 | 17.52x |
| 2026-06-08 | 17.23x |
| 2026-06-05 | 17.24x |
| 2026-06-04 | 17.24x |
| 2026-06-03 | 17.37x |
| 2026-06-02 | 17.04x |
| 2026-06-01 | 17.13x |
| 2026-05-29 | 17.34x |
| 2026-05-28 | 17.46x |
| 2026-05-27 | 17.36x |
| 2026-05-26 | 17.39x |
| 2026-05-22 | 17.53x |
| 2026-05-21 | 17.54x |
| 2026-05-20 | 17.45x |
| 2026-05-19 | 17.35x |
| 2026-05-18 | 17.58x |
| 2026-05-15 | 17.59x |
| 2026-05-14 | 17.26x |
| 2026-05-13 | 17.51x |
| 2026-05-12 | 17.62x |
| 2026-05-11 | 17.55x |
| 2026-05-08 | 17.54x |
| 2026-05-07 | 17.43x |
| 2026-05-06 | 17.32x |
| 2026-05-05 | 15.62x |
| 2026-05-04 | 21.26x |
| 2026-05-01 | 21.10x |
| 2026-04-30 | 21.33x |
| 2026-04-29 | 21.12x |
| 2026-04-28 | 20.99x |
| 2026-04-27 | 20.99x |
| 2026-04-24 | 21.11x |
| 2026-04-23 | 21.33x |
| 2026-04-22 | 21.15x |
| 2026-04-21 | 20.98x |
| 2026-04-20 | 20.94x |
| 2026-04-17 | 20.85x |
| 2026-04-16 | 20.86x |
| 2026-04-15 | 20.62x |
| 2026-04-14 | 20.95x |
| 2026-04-13 | 21.09x |
| 2026-04-10 | 20.99x |
| 2026-04-09 | 21.03x |
| 2026-04-08 | 20.88x |
| 2026-04-07 | 20.97x |
| 2026-04-06 | 21.00x |
| 2026-04-02 | 20.69x |
| 2026-04-01 | 21.01x |
| 2026-03-31 | 21.24x |
| 2026-03-30 | 21.15x |
| 2026-03-27 | 21.29x |
| 2026-03-26 | 21.44x |
| 2026-03-25 | 21.33x |
| 2026-03-24 | 21.21x |
| 2026-03-23 | 21.14x |
| 2026-03-20 | 20.94x |
| 2026-03-19 | 20.97x |
| 2026-03-18 | 20.91x |
| 2026-03-17 | 20.99x |
| 2026-03-16 | 20.87x |
| 2026-03-13 | 21.04x |
| 2026-03-12 | 21.19x |
| 2026-03-11 | 21.31x |
| 2026-03-10 | 21.09x |
| 2026-03-09 | 21.16x |
| 2026-03-06 | 21.04x |
| 2026-03-05 | 20.98x |
| 2026-03-04 | 21.31x |
| 2026-03-03 | 21.14x |
| 2026-03-02 | 21.26x |
| 2026-02-27 | 21.41x |
| 2026-02-26 | 21.16x |
| 2026-02-25 | 20.95x |
| 2026-02-24 | 21.05x |
| 2026-02-23 | 21.07x |
| 2026-02-20 | 21.04x |
| 2026-02-19 | 20.81x |
| 2026-02-18 | 20.84x |
| 2026-02-17 | 21.02x |
| 2026-02-13 | 20.92x |
| 2026-02-12 | 20.99x |
| 2026-02-11 | 20.60x |
| 2026-02-10 | 18.92x |
| 2026-02-09 | 18.82x |
| 2026-02-06 | 19.01x |
| 2026-02-05 | 19.48x |
| 2026-02-04 | 19.08x |
| 2026-02-03 | 18.66x |
| 2026-02-02 | 17.31x |
| 2026-01-30 | 17.21x |
| 2026-01-29 | 17.09x |
| 2026-01-28 | 17.01x |
| 2026-01-27 | 16.99x |
| 2026-01-26 | 17.10x |
| 2026-01-23 | 17.14x |
| 2026-01-22 | 17.20x |
| 2026-01-21 | 17.03x |
| 2026-01-20 | 16.90x |
| 2026-01-16 | 16.95x |
| 2026-01-15 | 17.01x |
| 2026-01-14 | 16.90x |
| 2026-01-13 | 16.93x |
| 2026-01-12 | 17.25x |
| 2026-01-09 | 17.33x |
| 2026-01-08 | 17.39x |
| 2026-01-07 | 17.30x |
| 2026-01-06 | 17.51x |
| 2026-01-05 | 17.47x |
| 2026-01-02 | 17.50x |
| 2025-12-31 | 17.45x |
| 2025-12-30 | 17.46x |
| 2025-12-29 | 17.45x |
| 2025-12-26 | 17.47x |
| 2025-12-24 | 17.50x |
| 2025-12-23 | 17.51x |
| 2025-12-22 | 17.62x |
| 2025-12-19 | 17.54x |
| 2025-12-18 | 17.60x |
| 2025-12-17 | 17.73x |
| 2025-12-16 | 17.70x |
| 2025-12-15 | 17.82x |
| 2025-12-12 | 17.89x |
| 2025-12-11 | 17.84x |
| 2025-12-10 | 17.74x |
| 2025-12-09 | 17.63x |
| 2025-12-08 | 17.65x |
| 2025-12-05 | 17.67x |
| 2025-12-04 | 17.66x |
| 2025-12-03 | 17.72x |
| 2025-12-02 | 17.77x |
| 2025-12-01 | 17.77x |
| 2025-11-28 | 17.80x |
| 2025-11-26 | 17.82x |
| 2025-11-25 | 17.89x |
| 2025-11-24 | 17.79x |
| 2025-11-21 | 17.83x |
| 2025-11-20 | 17.55x |
| 2025-11-19 | 17.54x |
| 2025-11-18 | 17.62x |
| 2025-11-17 | 17.66x |
| 2025-11-14 | 17.90x |
| 2025-11-13 | 17.99x |
| 2025-11-12 | 18.02x |
| 2025-11-11 | 17.95x |
| 2025-11-10 | 17.83x |
| 2025-11-07 | 18.03x |
| 2025-11-06 | 17.90x |
| 2025-11-05 | 17.88x |
| 2025-11-04 | 17.81x |
| 2025-11-03 | 17.76x |
| 2025-10-31 | 17.76x |
| 2025-10-30 | 17.74x |
| 2025-10-29 | 18.19x |
| 2025-10-28 | 17.18x |
| 2025-10-27 | 17.18x |
| 2025-10-24 | 17.15x |
| 2025-10-23 | 17.08x |
| 2025-10-22 | 17.15x |
| 2025-10-21 | 17.11x |
| 2025-10-20 | 17.09x |
| 2025-10-17 | 16.96x |
| 2025-10-16 | 16.92x |
| 2025-10-15 | 16.96x |
| 2025-10-14 | 17.00x |
| 2025-10-13 | 16.84x |
| 2025-10-10 | 16.84x |
| 2025-10-09 | 16.99x |
| 2025-10-08 | 17.08x |
| 2025-10-07 | 17.27x |
| 2025-10-06 | 17.09x |
| 2025-10-03 | 17.27x |
| 2025-10-02 | 17.33x |
| 2025-10-01 | 17.38x |
| 2025-09-30 | 17.38x |
| 2025-09-29 | 17.24x |
| 2025-09-26 | 17.25x |
| 2025-09-25 | 17.22x |
| 2025-09-24 | 17.42x |
| 2025-09-23 | 17.37x |
| 2025-09-22 | 17.27x |
| 2025-09-19 | 17.21x |
| 2025-09-18 | 17.22x |
| 2025-09-17 | 17.08x |
| 2025-09-16 | 17.21x |
| 2025-09-15 | 17.26x |
| 2025-09-12 | 17.39x |
| 2025-09-11 | 17.40x |
| 2025-09-10 | 17.34x |
| 2025-09-09 | 17.61x |
| 2025-09-08 | 17.47x |
| 2025-09-05 | 17.68x |
| 2025-09-04 | 17.54x |
| 2025-09-03 | 17.56x |
| 2025-09-02 | 17.62x |
| 2025-08-29 | 17.67x |
| 2025-08-28 | 17.57x |
| 2025-08-27 | 17.66x |
| 2025-08-26 | 17.72x |
| 2025-08-25 | 17.64x |
| 2025-08-22 | 17.83x |
| 2025-08-21 | 17.66x |
| 2025-08-20 | 17.65x |
| 2025-08-19 | 17.60x |
| 2025-08-18 | 17.40x |
| 2025-08-15 | 17.53x |
| 2025-08-14 | 17.47x |
| 2025-08-13 | 17.48x |
| 2025-08-12 | 17.33x |
| 2025-08-11 | 17.15x |
| 2025-08-08 | 17.17x |
| 2025-08-07 | 17.06x |
| 2025-08-06 | 17.07x |
| 2025-08-05 | 17.83x |
| 2025-08-04 | 13.20x |
| 2025-08-01 | 13.15x |
| 2025-07-31 | 13.24x |
| 2025-07-30 | 13.43x |
| 2025-07-29 | 13.50x |
| 2025-07-28 | 13.47x |
| 2025-07-25 | 13.46x |
| 2025-07-24 | 13.44x |
| 2025-07-23 | 13.74x |
| 2025-07-22 | 13.50x |
| 2025-07-21 | 13.20x |
| 2025-07-18 | 13.28x |
| 2025-07-17 | 13.38x |
| 2025-07-16 | 13.23x |
| 2025-07-15 | 13.25x |
| 2025-07-14 | 13.38x |
| 2025-07-11 | 13.34x |
| 2025-07-10 | 13.38x |
| 2025-07-09 | 13.31x |
| 2025-07-08 | 13.40x |
| 2025-07-07 | 13.35x |
| 2025-07-03 | 13.34x |
| 2025-07-02 | 13.34x |
| 2025-07-01 | 13.53x |
| 2025-06-30 | 13.34x |
| 2025-06-27 | 13.30x |
| 2025-06-26 | 13.27x |
| 2025-06-25 | 13.24x |
| 2025-06-24 | 13.27x |
| 2025-06-23 | 13.05x |
| 2025-06-20 | 13.08x |
| 2025-06-18 | 13.03x |
| 2025-06-17 | 13.06x |
| 2025-06-16 | 13.12x |
| 2025-06-13 | 13.04x |
| 2025-06-12 | 13.10x |
| 2025-06-11 | 13.14x |
| 2025-06-10 | 13.18x |
| 2025-06-09 | 13.12x |
| 2025-06-06 | 13.12x |
| 2025-06-05 | 13.12x |
| 2025-06-04 | 13.07x |
| 2025-06-03 | 13.04x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About DaVita Inc.
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- CEO
- Javier J. Rodriguez